# Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

> **NCT02508376** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 70 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **OTHER:** AP10-602
- **BIOLOGICAL:** GLA-SE
- **BIOLOGICAL:** ID93

## Key facts

- **NCT ID:** NCT02508376
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-22
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508376, "Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02508376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*